June 22, 2018 / 6:00 AM / 24 days ago

BRIEF-Pharnext To Announce Results From Phase 3 Trial Of Pxt3003 By October 2018

June 22 (Reuters) - PHARNEXT SA:

* ANNOUNCED ON THURSDAY UPDATE FROM PHASE 3 CLINICAL PROGRAM EVALUATING PXT3003 FOR TREATMENT OF CHARCOT-MARIE-TOOTH TYPE 1A DISEASE

* TOP-LINE RESULTS FROM PIVOTAL PLEO-CMT STUDY ARE NOW EXPECTED BY OCTOBER 2018 Source text for Eikon:

Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below